Kinsale Capital Group Inc. Raises Holdings in Amgen Inc. $AMGN

Posted by George Bondi on Aug 18th, 2026

Kinsale Capital Group Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 12.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,075 shares of the medical research company’s stock after purchasing an additional 4,564 shares during the period. Amgen comprises about 2.0% of Kinsale Capital Group Inc.’s holdings, making the stock its 13th largest position. Kinsale Capital Group Inc.’s holdings in Amgen were worth $15,236,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. High Note Wealth LLC grew its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after buying an additional 28 shares during the last quarter. Verus Capital Partners LLC lifted its stake in Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after buying an additional 28 shares during the last quarter. Destination Wealth Management boosted its holdings in shares of Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares during the period. Finally, Breakwater Capital Group boosted its holdings in shares of Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 29 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AMGN shares. Wells Fargo & Company lifted their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their price target on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. BMO Capital Markets raised their price objective on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Citigroup lifted their price objective on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $372.39.

Check Out Our Latest Stock Report on Amgen

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

Shares of AMGN opened at $419.38 on Tuesday. The stock has a market capitalization of $226.73 billion, a P/E ratio of 26.06, a P/E/G ratio of 3.86 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $421.79. The company’s fifty day moving average is $372.05 and its two-hundred day moving average is $359.47.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.